Novo Nordisk settles US patent fight with Viatris over Ozempic, Wegovy
Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic.
Mass. to play a key role as Novo Nordisk grows beyond Ozempic
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
Becker's Hospital Review12h
Novo Nordisk to invest $158M in insulin plant
Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.
Novo Nordisk to invest $158 million in insulin plant in Brazil
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...
Novo Nordisk's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Yahoo Finance3d
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
Novo Nordisk to Invest $158 Million in Brazilian Insulin Plant
Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...